Aligos Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aligos Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • Aligos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$19.3M, a 6.75% decline year-over-year.
  • Aligos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$77M, a 5.78% increase year-over-year.
  • Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$87.7M, a 8.71% increase from 2022.
  • Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$96M, a 25.2% increase from 2021.
  • Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$128M, a 18.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$87.7M +$8.37M +8.71% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-12
2022 -$96M +$32.3M +25.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-12
2021 -$128M -$19.8M -18.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$109M -$56.3M -108% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 -$52.3M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.